4521.T
KAKEN PHARMACEUTICAL CO.,LTD.
プライム · 医薬品 · 医薬品 · JP
JPY 3,960.00
+0.00%Year over year
Reported trailing growth
- Revenue
- -18.3%
- EBITDA
- —
- EBIT
- —
- EPS
- -84.7%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +12.3%
- EBITDA
- —
- EPS
- +7.5%
Three-year CAGR
- Revenue
- +1.7%
- EBITDA
- -41.1%
- EBIT
- —
- Net income
- -26.7%
- EPS
- -26.9%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026